Regulatory news

Peptide Compounding Policy: Citizen Petition and HHS Update

Published October 26, 2026 · 7 min read

Two things happened in the week of October 19, 2026 that changed the shape of the argument over peptide compounding in the United States. The HHS Secretary described the goal of a draft federal policy in a television interview, and a drug-safety advocacy group filed a formal citizen petition asking FDA to do the opposite. Neither event changes the law today. This article lays out what each side said, what is documented, and what is still unknown. It follows on from our earlier explainer on the HHS interim access policy.

Where things stand

An "Interim Access Policy for Compounding Using Certain Peptides" was submitted by HHS and FDA to the White House Office of Management and Budget for review in mid-October 2026. Sources give the date as October 14 or 15 (sources 1 and 2). The policy text had not been made public in the coverage we found, and HHS did not respond to the Epoch Times request for details (source 1). Reuters, as republished, described the proposal as something that could make it easier for pharmacies to compound certain peptides, and said the peptides in question have not been approved by FDA as safe or effective (source 3).

The general mechanism is enforcement discretion: a regulator states that, under specified conditions and for a limited time, it does not intend to take action against particular conduct. It would not approve any product, and it would not change the underlying statute. The draft's eligible substances, conditions and effective date were not public as of this writing (source 2).

The advisory committee vote it builds on

In July 2026 FDA's Pharmacy Compounding Advisory Committee reviewed seven substances: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon. It voted to recommend six for the 503A bulk drug substances list and not to recommend emideltide (sources 3, 4 and 5). Two points matter for reading that vote. First, advisory committee votes are recommendations; they do not by themselves add anything to a list. Second, reporting describes the vote as going against the position of FDA's own staff reviewers, who had recommended against bulk compounding of the seven substances (sources 3 and 5, with the staff position as characterized by the petitioner and by Reuters).

What the HHS Secretary said

On Tuesday, October 20, in an interview on Fox News, Secretary Robert F. Kennedy Jr. was asked about the FDA policy change. According to Reuters he said "Americans are going to be buying these anyway," and described the goal as "a regulated marketplace, so that what they're getting is what they claim to be" (source 3). The Regulatory Affairs Professionals Society summarized his remarks as describing a state-regulated marketplace reached through 503A compounders, as a way to protect consumers who might otherwise buy from gray- or black-market sellers (source 6). The Reuters text we reviewed does not mention state regulation, so we attribute that wording only to the RAPS summary.

It is worth separating what that statement is from what it is not. It is a statement of policy intent in an interview. It is not the policy, which was still under review, and it is not evidence about the compounds themselves. The argument embedded in it is a harm-reduction one: if demand exists regardless, a regulated channel is safer than an unregulated one. That argument depends on factual questions (what is in the products, how pharmacies would be overseen, what the evidence shows) that the interview did not address.

The citizen petition

On October 21, 2026 the Partnership for Safe Medicines (PSM), a drug-safety advocacy group, announced that it had filed a citizen petition with FDA (source 4). A citizen petition is a formal request that FDA take or refrain from an action; FDA is required to respond, but a petition has no legal force on its own and the agency's answer can take months. According to PSM's release, the petition asks FDA to block compounding of the peptides by any route and to disregard the July committee meeting as a basis for future rulemaking (source 4).

PSM's stated arguments, which are the group's claims rather than findings:

• Process. PSM alleges the committee was constituted in violation of the Federal Advisory Committee Act and the Ethics in Government Act, and that newly appointed members have financial ties to the peptide industry.
• Evidence. PSM says FDA scientists found "no adequate characterization, extremely limited safety data, and no meaningful human evidence" for the substances.
• Practice. PSM says its own test purchases from four 503A pharmacies in Texas and Pennsylvania, shipped to California, arrived from pharmacies it says lacked required California licenses (three had no known California license, and the fourth lacked a non-resident sterile compounding license). It also says none of the products were labeled "research use only" and all came with syringes and injection instructions.

These are allegations in an advocacy group's press release. We have not seen a response from the pharmacies or from FDA, and we did not review the petition document itself. The group's executive director is quoted as saying that compounders illegally producing and selling unapproved peptides today should be prosecuted (source 4).

What is documented about the evidence base

The disagreement is partly legal and partly about evidence, so it helps to keep the documented parts apart from the contested parts. A 2026 ProPublica investigation reported that FDA's 2023 decision to place 19 peptides in "Category 2," its list of substances it considered too risky for compounding, was supported by documented safety concerns, according to three former FDA officials, and that there has been little new science on those peptides since 2023 (source 7). FDA's own reviewers cited well-established risks of immune reactions to injectable peptides, limited human data for most of the substances, and, where human data existed, signals that raised concerns without enough data to resolve them (source 7). Those are characterizations by journalists and former officials of the agency's reviews. They are not new trial data.

What has not appeared is the thing that would settle the factual part of the dispute: controlled human studies of these substances at a scale that could estimate benefit and risk. Compounding policy can change who is allowed to make a product without producing that evidence. That is the heart of the safety objection, and it is also why supporters point to the alternative of unregulated products whose contents nobody has checked.

Why product identity keeps coming up

Both camps return to the same practical question: does the product contain what the label says, at the stated amount, free of contaminants? That is a documentation question, not a policy one. It is answered, if at all, by lot-level testing and traceability (see Peptide Testing Explained and what adverse event reports can and cannot show). Regulatory status also does not substitute for it: a "research use only" label is not a legal safe harbor either, a point addressed in our piece on what research use only means.

What to watch next

• Whether OMB clears the interim policy and whether its text is published, including which substances it names and what conditions it sets.
• FDA's response to the PSM petition, and any challenge to the committee's composition.
• A second advisory committee meeting on five more peptides, which earlier reporting expected by the end of February 2027.
• State pharmacy-board and state-law responses, which govern compounding in practice.

Limitations of this article

• It relies on news reports, a law-firm and trade-press summary, and one advocacy group's press release; the draft policy and the petition itself were not reviewed.
• Sources disagree on the exact date the policy was submitted for review (October 14 or 15).
• Characterizations of FDA staff positions come from reporters, former officials and the petitioner, not from FDA documents we reviewed.
• Nothing here evaluates any compound's safety or effectiveness.

The short version

A draft federal policy that could loosen enforcement against compounding certain peptides is under White House review, the HHS Secretary has said he wants "a regulated marketplace," and a drug-safety group has asked FDA to block the whole approach on legal and safety grounds. None of this is final, and none of it adds human safety data. Treat statements on both sides as positions to be tested against the policy text and the evidence once each is public.

Sources

1. The Epoch Times, "RFK Jr.'s Agency Sends Plan for Peptide Drugs to White House," Oct 15, 2026: theepochtimes.com
2. Global Healthcare Magazine, "FDA Peptide Compounding Policy Change Begins Amid The White House Review," as of Oct 16, 2026: globalhealthcaremagazine.com
3. Reuters (Jones and Aboulenein), "Kennedy says Trump administration aims for regulated market for peptides," Oct 20, 2026, as republished by GV Wire: gvwire.com
4. Partnership for Safe Medicines, press release on its citizen petition, Oct 21, 2026 (advocacy group; claims are its own): safemedicines.org
5. AJMC, "FDA Panel Backs 6 Peptides for Compounding" (July 2026 committee vote): ajmc.com
6. RAPS, "This Week at FDA: Peptide dispute, clinical trial legislation, and more," Oct 23, 2026: raps.org
7. ProPublica (Anjeanette Damon), "Peptide safety, FDA and compounding pharmacies," Apr 3, 2026: propublica.org

Related reading

• HHS Peptide Interim Access Policy
• What Research Use Only Means
• What FDA Adverse Event Reports Can and Can’t Show
• Glossary

← Back to all articles